keyword
MENU ▼
Read by QxMD icon Read
search

Macular oedema

keyword
https://www.readbyqxmd.com/read/29140735/factors-associated-with-visual-acuity-in-patients-with-cystoid-macular-oedema-and-retinitis-pigmentosa
#1
Gerald Liew, Anthony T Moore, Patrick D Bradley, Andrew R Webster, Michel Michaelides
PURPOSE: Retinitis pigmentosa is the most common inherited retinal dystrophy. The factors associated with visual acuity in patients with other retinal diseases are well known, but are poorly understood in patients with retinitis pigmentosa. This knowledge is useful for prognosis and to support secondary endpoints in clinical trials. METHODS: We conducted a cross-sectional study of consecutive patients recruited from the inherited retinal disease service from January 2012 to December 2012...
November 15, 2017: Ophthalmic Epidemiology
https://www.readbyqxmd.com/read/29134696/refractive-changes-after-intravitreal-ranibizumab-injections-for-diabetic-macular-oedema
#2
Irini Chatziralli, Athanasios Chatzipantelis, Eleni Dimitriou, Evgenia Mpourouki, George Theodossiadis, Panagiotis Theodossiadis
PURPOSE: The purpose of this study was to evaluate refractive changes after intravitreal ranibizumab injections for the treatment of diabetic macular oedema. METHODS: Participants in this retrospective study were 35 patients (35 eyes) with diabetic macular oedema, who received intravitreal ranibizumab injections. Spherical equivalent refractive power was evaluated before treatment and at least one month after the last injection where no fluid existed. Demographic characteristics, visual acuity, central retinal thickness and the number of injections were recorded and analysed...
November 14, 2017: Clinical & Experimental Optometry: Journal of the Australian Optometrical Association
https://www.readbyqxmd.com/read/29127134/radiation-retinopathy-treated-successfully-with-aflibercept
#3
Pakinee Pooprasert, Tafadzwa Young-Zvandasara, Ayad Al-Bermani
Aflibercept (aflibercept) is a novel anti-vascular endothelial growth factor drug indicated for wet age-related macular degeneration and macular oedema secondary to retinal vein occlusion and diabetic macular oedema. While only newly introduced on the market, it is growing in popularity and over 5.5 million doses have been prescribed worldwide. Due to its versatile mechanism, it is indicated for numerous eye pathologies, and in particular, has been adapted to treat various types of retinopathy. To our knowledge, this is the first case report of solely using aflibercept to treat cystoid macular oedema in radiation retinopathy...
November 9, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/29117007/ocular-features-of-cerebro-costo-mandibular-syndrome
#4
Zoya Hameed, Simon Taylor, Dan Lindfield
Cerebro-costo-mandibular syndrome is a rare hereditary disorder characterised by micrognathia, posterior rib gaps, and secondary developmental delay. Patients often require ventilation and feeding support throughout life. We describe the first reported ophthalmic findings of CCMS and propose that defects in choroidal permeability lead to chronic macular oedema and refractory aqueous misdirection syndrome. Here we discuss the medical and surgical management concerns of recurrent angle closure and raised intraocular pressure in a CCMS patient...
November 7, 2017: Journal of Glaucoma
https://www.readbyqxmd.com/read/29099501/efficacy-and-timing-of-adjunctive-therapy-in-the-anti-vegf-treatment-regimen-for-macular-oedema-in-retinal-vein-occlusion-12-month-real-world-result
#5
P L Lip, P Cikatricis, A Sarmad, E M Damato, R Chavan, A Mitra, S Elsherbiny, Y Yang, B Mushtaq
PurposeVarious combination treatment regimens have been tried to improve the short-term efficacy of intravitreal monotherapy for the treatment of macular oedema (MO) secondary to retinal vein occlusion (RVO). Our study introduces the RandOL protocol (Ranibizumab and Ozurdex with Laser photocoagulation) of initial anti-VEGF therapy, controlling recurrent non-ischaemic MO with an intravitreal steroid and applying laser therapy to non-perfused retina. We describe our 12-month follow-up experience on timing for adjunctive therapy and real-world effectiveness and safety data...
November 3, 2017: Eye
https://www.readbyqxmd.com/read/29090846/the-relation-study-efficacy-and-safety-of-ranibizumab-combined-with-laser-photocoagulation-treatment-versus-laser-monotherapy-in-npdr-and-pdr-patients-with-diabetic-macular-oedema
#6
Gabriele E Lang, Sandra Liakopoulos, Jessica Vögeler, Claudia Weiß, Georg Spital, Maria-Andreea Gamulescu, Chris Lohmann, Peter Wiedemann
PURPOSE: To assess efficacy and safety of intravitreal ranibizumab 0.5 mg plus laser (COMBI) versus laser monotherapy (LASER) in patients with visual impairment due to diabetic macular oedema (DME) in either nonproliferative diabetic retinopathy (NPDR) or proliferative diabetic retinopathy (PDR) and to analyse the relevance of inner versus outer retinal thickness. METHODS: In this double-masked, multicentre phase IIIb study, patients (N = 128) were randomized (2:1) to receive COMBI (n = 85) versus LASER (n = 43)...
November 1, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/29063703/analysis-of-retinal-layer-thickness-in-diabetic-macular-oedema-treated-with-ranibizumab-or-triamcinolone
#7
Sonja G Prager, Jan Lammer, Christoph Mitsch, Julia Hafner, Berthold Pemp, Christoph Scholda, Michael Kundi, Ursula Schmidt-Erfurth, Katharina Kriechbaum
PURPOSE: To evaluate detailed changes in retinal layer thickness in spectral-domain optical coherence tomography (SD-OCT) images during a 1-year follow-up of patients treated for diabetic macula oedema (DME). METHODS: Post hoc analysis of retinal layer thickness changes applying the automated layer segmentation of SD-OCT images in eyes with DME that were randomly assigned to receive pro re nata (PRN) treatment with either 0.5 mg ranibizumab or 8 mg triamcinolone...
October 24, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/29061629/a-longitudinal-study-to-assess-the-frequency-and-cost-of-antivascular-endothelial-therapy-and-inequalities-in-access-in-england-between-2005-and-2015
#8
William Hollingworth, Tim Jones, Barnaby C Reeves, Tunde Peto
OBJECTIVES: High-cost antivascular endothelial growth factor (anti-VEGF) medicines for eye disorders challenge ophthalmologists and policymakers to provide fair access for patients while minimising costs. We describe the growth in the use and costs of these medicines and measure inequalities in access. DESIGN: Longitudinal study using Hospital Episode Statistics (2005/2006 to 2014/2015) and hospital prescribing cost reports (2008/2009 to 2015/2016). We used Poisson regression to estimate standardised rates and explore temporal and geographical variations...
October 22, 2017: BMJ Open
https://www.readbyqxmd.com/read/29051325/impact-of-baseline-diabetic-retinopathy-severity-scale-scores-on-visual-outcomes-in-the-vivid-dme-and-vista-dme-studies
#9
Giovanni Staurenghi, Nicolas Feltgen, Jennifer J Arnold, Todd A Katz, Carola Metzig, Chengxing Lu, Frank G Holz
BACKGROUND/AIMS: To evaluate intravitreal aflibercept versus laser in subgroups of patients with baseline Diabetic Retinopathy Severity Scale (DRSS) scores ≤43, 47, and ≥53 in VIVID-DME and VISTA-DME. METHODS: Patients with diabetic macular oedema were randomised to receive intravitreal aflibercept 2 mg every 4 weeks (2q4), intravitreal aflibercept 2 mg every 8 weeks after five initial monthly doses (2q8), or macular laser photocoagulation at baseline with sham injections at every visit...
October 19, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/29038766/external-validation-of-cut-off-points-for-foveal-thickness-taking-into-account-the-intraretinal-fluid-using-optical-coherence-tomography-to-diagnose-diabetic-macular-oedema
#10
Carmen Hernández-Martínez, Antonio Palazón-Bru, Cesar Azrak, Aída Navarro-Navarro, Manuel Vicente Baeza-Díaz, José Juan Martínez-Toldos, Vicente Francisco Gil-Guillén
BACKGROUND: In late 2015, cut-off points were published for foveal thickness to diagnose diabetic macular oedema taking into account the presence of intraretinal fluid using optical coherence tomography (OCT) in primary care patients (90 µm in the presence of intraretinal fluid and 310 µm otherwise). METHODS: This cross-sectional observational study was carried out on 134 eyes of diabetic patients treated in specialised ophthalmology services in a Spanish region in 2012-2013, to externally validate the aforementioned cut-off points...
2017: PeerJ
https://www.readbyqxmd.com/read/28950262/dexamethasone-intravitreal-implant-therapy-for-retinal-vein-occlusion-macular-oedema-and-conversion-to-ranibizumab-in-clinical-practice
#11
Shafi Balal, Jonathan Than, Sharmila Tekriwal, Aires Lobo
PURPOSE: Evaluation of outcomes in retinal vein occlusions (RVOs) for: (1) multiple repeat dexamethasone (DEX) injections and (2) conversion from DEX to ranibizumab. METHODS: We conducted a retrospective study evaluating outcomes of multiple DEX injections and those requiring conversion to ranibizumab at Moorfields Eye Hospital, Bedford, UK. All patients had undergone a complete ophthalmic work-up. RESULTS: Patients (n = 129) had a mean follow-up of 19...
September 27, 2017: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/28931295/-two-year-follow-up-results-of-patients-with-macular-oedema-due-to-retinal-vein-occlusion-treated-with-ranibizumab
#12
Z Hladíková, E Klofáčová, B Kalvodová
PURPOSE: To evaluate 2-year follow-up results of patients with macular oedema (ME) caused by central (CRVO) and branch (BRVO) retinal vein occlusion treated with intravitreal ranibizumab at the Department of Ophthalmology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic. METHODS: Retrospective study. RESULTS: The 2-year follow-up was completed by 18 patients with ME caused by CRVO and 16 patients with ME caused by BRVO...
2017: Ceská a Slovenská Oftalmologie
https://www.readbyqxmd.com/read/28926197/epiretinal-membrane-surgery-an-analysis-of-2-step-sequential-or-combined-phacovitrectomy-surgery-on-refraction-and-macular-anatomy-in-a-prospective-trial
#13
Hassan Hamoudi, Ulrik Correll Christensen, Morten La Cour
PURPOSE: To assess the impact of combined phacoemulsification-vitrectomy and sequential surgery for idiopathic epiretinal membrane (ERM) on refractive error (RE) and macular morphology. METHODS: In this prospective clinical trial, we allocated phakic eyes with ERM to (1) cataract surgery and subsequent pars plana vitrectomy (PPV) (CAT group), (2) PPV and subsequent cataract surgery (VIT group) or (3) phaco-vitrectomy (COMBI group). Examinations were at baseline, one month after each surgery, and at 3 months and 12 months of follow-up...
September 19, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/28922697/low-frequency-ranibizumab-versus-dexamethasone-implant-for-macular-oedema-secondary-to-branch-retinal-vein-occlusion
#14
Bora Yuksel, Omer Karti, Ozan Celik, Suleyman Gokhan Kerci, Tuncay Kusbeci
BACKGROUND: The aim was to make a real-world comparison of the efficacy of ranibizumab, dexamethasone and grid laser treatments in macular oedema due to branch retinal vein occlusion (BRVO). METHODS: Forty-four eyes of 44 consecutive patients with macular oedema secondary to BRVO were included. Treatment arms comprised standard care (StCARE, n = 15), intravitreal ranibizumab (RNB, n = 14) and dexamethasone implant (DEX, n = 15). No rescue laser was performed in DEX and RNB groups...
September 18, 2017: Clinical & Experimental Optometry: Journal of the Australian Optometrical Association
https://www.readbyqxmd.com/read/28911260/two-year-results-from-a-phase-2-extension-study-of-oral-amiselimod-in-relapsing-multiple-sclerosis
#15
Ludwig Kappos, Douglas L Arnold, Amit Bar-Or, A John Camm, Tobias Derfuss, Till Sprenger, Martin Davies, Alexandra Piotrowska, Pingping Ni, Tomohiko Harada
BACKGROUND: Amiselimod, an oral selective sphingosine-1-phosphate 1 receptor modulator, suppressed disease activity dose-dependently without clinically relevant bradyarrhythmia in a 24-week phase 2, placebo-controlled study in relapsing-remitting multiple sclerosis. OBJECTIVE: To assess safety and efficacy of amiselimod over 96 weeks. METHODS: After completing the core study, patients on amiselimod continued at the same dose, whereas those on placebo were randomised 1:1:1 to amiselimod 0...
September 1, 2017: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28892948/microperimetry-a-new-tool-for-assessing-retinal-sensitivity-in-macular-diseases
#16
Memota Laishram, Krishnagopal Srikanth, A R Rajalakshmi, Swathi Nagarajan, G Ezhumalai
INTRODUCTION: Macular disease is the leading cause of low vision in the Western world. Drusen and pigmentary irregularities are common among the rural Northern Indian population. The disease process leads to loss of central vision, metamorphopsia, macropsia or micropsia and colour vision defect. AIM: To study the retinal sensitivity changes in macular diseases using microperimetry. MATERIALS AND METHODS: It was an observational study, conducted in the Department of Ophthalmology at a rural tertiary care hospital...
July 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28881490/diabetic-retinopathy-screening-using-deep-neural-network
#17
Nishanthan Ramachandran, Hong Sheng Chiong, Mary Jane Sime, Graham A Wilson
Importance There is a burgeoning interest in the use of deep neural network in diabetic retinal screening. BACKGROUND: To determine whether a deep neural network could satisfactorily detect diabetic retinopathy that requires referral to an ophthalmologist from a local diabetic retinal screening programme and an international database. Design Retrospective audit Samples Diabetic retinal photos from Otago database photographed during October 2016 (485 photos); and 1200 photos from Messidor international database...
September 7, 2017: Clinical & Experimental Ophthalmology
https://www.readbyqxmd.com/read/28837425/aflibercept-bevacizumab-or-ranibizumab-for-diabetic-macular-oedema-recent-clinically-relevant-findings-from-drcr-net-protocol-t
#18
REVIEW
Sophie Cai, Neil M Bressler
PURPOSE OF REVIEW: The aim of this study was to provide clinically relevant findings from the DRCR.net Protocol T, a multicentre randomized clinical trial comparing intravitreous aflibercept, repackaged (compounded) bevacizumab and ranibizumab for vision-impairing centre-involved diabetic macular oedema (DME). RECENT FINDINGS: At 1 year, all three antivascular endothelial growth factor (anti-VEGF) drugs, on average, improved visual acuity. There was no difference among drugs in mean change in visual acuity from baseline among eyes with baseline Snellen equivalent visual acuity of 20/32 to 20/40, whereas aflibercept yielded superior vision outcomes among eyes with baseline visual acuity of 20/50 to 20/320...
November 2017: Current Opinion in Ophthalmology
https://www.readbyqxmd.com/read/28834972/-healthcare-research-into-anti-vegf-therapy-selection-and-methodological-precautions
#19
Focke Ziemssen, Andreas Stahl, Spyridon Dimopoulos
Health care research has emerged as an approach to assess and improve quality of care and patient outcomes in the real world. It also has the potential to reduce healthcare costs by providing evidence to guide healthcare decisions.Randomised controlled trials (RCTs) theoretically offer the ideal study design to support treatment decisions. In RCTs, randomisation (formal chance) determines treatment allocation, which prevents selection bias from distorting the parameters of anti-VEGF treatment effects. Despite this advantage, only a minority of patients qualify for inclusion in neovascular age-related macular degeneration or diabetic macular oedema trials, which limits the validity of the results to the whole patient population seen in clinical practice...
August 23, 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/28814412/long-term-outcomes-with-as-needed-aflibercept-in-diabetic-macular-oedema-2-year-outcomes-of-the-endurance-extension-study
#20
Charles C Wykoff, William C Ou, Rahul N Khurana, David M Brown, W Lloyd Clark, David S Boyer
BACKGROUND/AIMS: To evaluate the efficacy and safety of individualised 2.0 mg intravitreal aflibercept retreatment for diabetic macular oedema (DME) through the fifth year of management. METHODS: This is a phase IV, 2-year, open-label extension study. Sixty patients completing the 3-year VISTA DME (Study of Intravitreal Aflibercept Injection in Patients With Diabetic Macular Edema) phase III trial enrolled in the ENDURANCE (Long-Term Efficacy and Safety of Intravitreal Aflibercept for the Treatment of DME in Subjects Who Completed the VISTA DME Trial) extension study...
August 16, 2017: British Journal of Ophthalmology
keyword
keyword
102386
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"